Thelansis

 Refractory angina (RA) is typically characterized as a persistent condition lasting at least three months, marked by angina in the presence of coronary artery disease (CAD) that remains unresponsive to a combination of optimal medical treatment, angioplasty, or bypass surgery. It is also confirmed that reversible myocardial ischemia is the underlying cause of the symptoms. Due to the complexity of CAD and relevant comorbidities, surgical or percutaneous coronary revascularization is not deemed a viable option for these patients. ·        According to Thelansis disease modeling, the estimated incidence of RA is approximately 8% to 15% among patients who undergo cardiac catheterization. ·        The annual number of newly diagnosed RA patients in the United States is approximately 87,000. The estimated annual incidence in Europe ranges between approximately 38,000 and 57,400 new cases.   Thelansis’s “Refractory...